Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation

Phase 2CompletedNCT00255281

AstraZeneca160 enrolled

Overview

The current study is designed to assess the efficacy and safety of iv AZD7009 in conversion from AF

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

160

Conditions

Atrial Fibrillation

Interventions

AZD7009, no generic name availableDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical indication for cardioversion of Atrial Fibrillation. Effective oral anticoagulation according to local routines or a TEE without any finding of intracardial thrombus or signs of thrombogenecity Exclusion Criteria: * Clinically significant sinus and/or AV node dysfunction. Serum or plasma potassium \<3.8 mmol/L or \>5.0 mmol/L. QTc(Bazett) \>450 ms. Any QRS duration \>150 ms

Locations (32)

Research Site

Esbjerg, Denmark

Outcomes

Primary Outcomes

The proportion of patients that have converted from AF within 90 minutes from start of infusion.

Secondary Outcomes

The time to conversion of AF from start of the infusion.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.